Companies /Healthcare

ImmunityBio Inc

NASDAQ: IBRX Biotechnology
$8.77
▲ $0.35 (+4.16%) today
Markets closed · 8:00pm ET

24/7 Wall St. View

Price Prediction Our analysts’ 12-month view: target, optimistic case, and floor. IBRX price prediction →

IBRX at a Glance

Valuation
Market cap
$8.9B
Profitability
Revenue (TTM)
$165.8M
EPS (TTM)
$-0.97
Price
52-week range
$2 – $12
Street target
$14.25
Earnings
Next report
Nov 3, 2026

Headquartered in San Diego, CA Fiscal year ends December NASDAQ: IBRX immunitybio.com

About ImmunityBio

ImmunityBio is a commercial-stage biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system to fight cancer and infectious diseases. The company's approach harnesses both the adaptive and innate immune systems to restore immune function and generate lasting immunological memory. Its core platform, Cancer BioShield, is centered on ANKTIVA, a proprietary IL-15 superagonist antibody-cytokine fusion protein that stimulates natural killer cells, cytotoxic T cells, and memory T cells. ANKTIVA is approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ and is now approved or authorized in five regulatory jurisdictions spanning 34 countries. The company's pipeline extends into non-small cell lung cancer, hematologic malignancies, and additional bladder cancer indications, complemented by a portfolio including adenovirus-vectored vaccines, allogeneic and autologous NK-cell therapies, and immunomodulators. ImmunityBio trades on NASDAQ under the ticker IBRX. Updated

Latest Activity

House trade disclosureLisa C. McClainU.S. Representative (R-MI), House Republican Conference Chair
  • CACICACI International, Inc. Class A Common Stock (CACI)Buy$15K – $50KSep 14
  • CATCaterpillar, Inc. Common Stock (CAT)Buy$1K – $15KSep 28
  • IBRXImmunityBio, Inc. - Common Stock (IBRX)Buy$1K – $15KSep 30
  • IBRXImmunityBio, Inc. - Common Stock (IBRX)Buy$1K – $15KSep 28
  • MSFTMicrosoft Corporation - Common Stock (MSFT)Buy$1K – $15KSep 30
  • NGNovagold Resources Inc. (NG)Buy$1K – $15KSep 14
  • OLNOlin Corporation Common Stock (OLN)Buy$15K – $50KSep 14
  • STXSeagate Technology Holdings PLC - Ordinary Shares (STX)Partial sell$15K – $50KSep 30
+ 1 more trades in this filing
Made public 28 days after the earliest trade

The House GOP conference chair's spouse put the three biggest tickets into defense IT, chlorine chemicals and offshore drilling, each in the $15,000 to $50,000 range, while trimming Seagate. Nine buys across one September stretch, disclosed 28 days after the first trade, lands days after the Senate shelved a congressional trading ban.

Read more

IBRX Coverage

Frequently Asked Questions

What does ImmunityBio do?

ImmunityBio is a commercial-stage biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system to fight cancer and infectious diseases.

What is the IBRX stock price target?

The Wall Street consensus 12-month price target for IBRX is $14.25. IBRX price prediction →